Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02347605 · ClinicalTrials.gov registry record · NA

Medicinal Nicotine for Preventing Cue Induced Craving

A NA study of Tobacco Use Disorder, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
56
Enrollment target
1
Study location

NCT02347605 is a NA study of Tobacco Use Disorder that has completed, run by University of Minnesota. The registered enrollment target is 56 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02347605, a NA study of Tobacco Use Disorder, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if changing the timeframe (relative to cue presentation) at which the nicotine lozenge is given can attenuate the increase in symptoms of tobacco craving and withdrawal that occur when smokers are presented with smoking cues. In this cross-over study, all subjects attend three laboratory sessions at which either nicotine lozenge or placebo is given prior to presentation of smoking cues or after presentation of smoking cues. The order in which the three conditions will be presented are randomized.

Conditions Studied

Interventions

  • DRUG Nicotine lozenge 4 mg
  • DRUG Placebo lozenge

Study Locations (1)

Minnesota

  • Clinical and Translational Sciences Institute - Minneapolis

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2013-09
Est. Completion 2015-01
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT02347605

The ClinicalTrials.gov registry entry for NCT02347605 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (77% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Nicotine lozenge 4 mg is the first listed.

NCT02347605 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02347605 about?

NCT02347605 is a clinical study titled "Medicinal Nicotine for Preventing Cue Induced Craving". The purpose of this study is to determine if changing the timeframe (relative to cue presentation) at which the nicotine lozenge is given can attenuate the increase in symptoms of tobacco craving and withdrawal that occur when smokers are presented with smoking cues. In this cross-over study, all su...

What is the current status of trial NCT02347605?

This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2013-09. Estimated completion is 2015-01.

What conditions does trial NCT02347605 study?

This clinical trial studies the following conditions: Tobacco Use Disorder.

What interventions are being tested in trial NCT02347605?

The interventions under investigation include: Nicotine lozenge 4 mg (DRUG), Placebo lozenge (DRUG).

Who is sponsoring clinical trial NCT02347605?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02347605 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.